The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study.

Koska J, Migrino RQ, Chan KC, Cooper-Cox K, Reaven PD

Diabetes care25 Jan 2021Cited by 27 (Europe PMC)

PMID33495294PMCIDPMC8247511DOI10.2337/dc20-2014PepBankPUB-33495294

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, exenatide reduced HbA1c versus placebo.
In plain wordsIn type 2 diabetes, exenatide lowered HbA1c more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c
Study
n = 163
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · up to 18 monthsAs given in this study (human).
Measurements
HbA1c estimated difference vs placebo
0.55%
exenatide versus placebo
Source sentences
Summary
Exenatide reduced hemoglobin A_1c (HbA_1c) (estimated difference vs. placebo 0.55%, P = 0.0007) and fasting and postmeal plasma glucose (19 mg/dL, P = 0.0002, and 25 mg/dL, P < 0.0001, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54).
Report a problemFND-3349529401
02HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, exenatide reduced fasting glucose versus placebo.
In plain wordsIn type 2 diabetes, exenatide lowered fasting blood sugar more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting plasma glucose
Study
n = 163
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · up to 18 monthsAs given in this study (human).
Measurements
Fasting plasma glucose difference vs placebo
19 mg/dL
exenatide versus placebo
Source sentences
Summary
Exenatide reduced hemoglobin A_1c (HbA_1c) (estimated difference vs. placebo 0.55%, P = 0.0007) and fasting and postmeal plasma glucose (19 mg/dL, P = 0.0002, and 25 mg/dL, P < 0.0001, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54).
Report a problemFND-3349529402
03HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, exenatide reduced postmeal glucose versus placebo.
In plain wordsIn type 2 diabetes, exenatide lowered blood sugar after meals more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostmeal plasma glucose
Study
n = 163
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · up to 18 monthsAs given in this study (human).
Measurements
Postmeal plasma glucose difference vs placebo
25 mg/dL
exenatide versus placebo
Source sentences
Summary
Exenatide reduced hemoglobin A_1c (HbA_1c) (estimated difference vs. placebo 0.55%, P = 0.0007) and fasting and postmeal plasma glucose (19 mg/dL, P = 0.0002, and 25 mg/dL, P < 0.0001, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54).
Report a problemFND-3349529403
04HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, carotid plaque volume change did not differ between exenatide and placebo.
In plain wordsIn type 2 diabetes, artery plaque volume changed similarly with exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeCarotid plaque volume
Study
n = 163
Comparator
Placebo
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · up to 18 monthsAs given in this study (human).
Measurements
Carotid plaque volume change
0.3%
exenatide
Carotid plaque volume change
−2.2%
placebo
Source sentences
Summary
Mean (SD) change in plaque volume in the exenatide group (0.3% [2%]) was not different from that in the placebo group (-2.2% [8%]) (P = 0.4).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54).
Report a problemFND-3349529404
05HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, plaque composition change did not differ between exenatide and placebo.
In plain wordsIn type 2 diabetes, plaque composition changed similarly with exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePlaque composition
Study
n = 163
Comparator
Placebo
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · up to 18 monthsAs given in this study (human).
Source sentences
Summary
There were no differences in changes in plaque composition, body weight, blood pressure, fasting and postmeal plasma triglycerides, and endothelial function between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54).
Report a problemFND-3349529408
06HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, weight change did not differ between exenatide and placebo.
In plain wordsIn type 2 diabetes, weight changed similarly with exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBody weight
Study
n = 163
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · up to 18 monthsAs given in this study (human).
Source sentences
Summary
There were no differences in changes in plaque composition, body weight, blood pressure, fasting and postmeal plasma triglycerides, and endothelial function between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54).
Report a problemFND-3349529409
07HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, blood pressure change did not differ between exenatide and placebo.
In plain wordsIn type 2 diabetes, blood pressure changed similarly with exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBlood pressure
Study
n = 163
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · up to 18 monthsAs given in this study (human).
Source sentences
Summary
There were no differences in changes in plaque composition, body weight, blood pressure, fasting and postmeal plasma triglycerides, and endothelial function between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54).
Report a problemFND-3349529410
08HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, fasting triglyceride change did not differ between exenatide and placebo.
In plain wordsIn type 2 diabetes, fasting blood fats changed similarly with exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFasting plasma triglycerides
Study
n = 163
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · up to 18 monthsAs given in this study (human).
Source sentences
Summary
There were no differences in changes in plaque composition, body weight, blood pressure, fasting and postmeal plasma triglycerides, and endothelial function between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54).
Report a problemFND-3349529411
09HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, postmeal triglyceride change did not differ between exenatide and placebo.
In plain wordsIn type 2 diabetes, blood fats after meals changed similarly with exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePostmeal plasma triglycerides
Study
n = 163
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · up to 18 monthsAs given in this study (human).
Source sentences
Summary
There were no differences in changes in plaque composition, body weight, blood pressure, fasting and postmeal plasma triglycerides, and endothelial function between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54).
Report a problemFND-3349529412
10HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, endothelial function change did not differ between exenatide and placebo.
In plain wordsIn type 2 diabetes, blood vessel function changed similarly with exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeEndothelial function
Study
n = 163
Comparator
Placebo
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · up to 18 monthsAs given in this study (human).
Source sentences
Summary
There were no differences in changes in plaque composition, body weight, blood pressure, fasting and postmeal plasma triglycerides, and endothelial function between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54).
Report a problemFND-3349529413
11HumanObservational studyOther
In exenatide-treated patients, plaque volume change correlated with HbA1c change.
In plain wordsIn patients taking exenatide, plaque volume change was linked to HbA1c change.
Peptide
Exenatide (exendin-4)
Outcome
Not applicablePlaque volume association with HbA1c
Study
n: not reported in source
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · up to 18 monthsAs given in this study (human).
Measurements
Correlation r, plaque volume change vs HbA1c change
0.38 r
exenatide group
Source sentences
Summary
The change in plaque volume in the exenatide group was associated with changes in HbA_1c (r = 0.38, P = 0.0004), body weight, and overall plasma glucose (r = 0.29, P = 0.007 both).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54).
Report a problemFND-3349529405
12HumanObservational studyOther
In exenatide-treated patients, plaque volume change correlated with body weight change.
In plain wordsIn patients taking exenatide, plaque volume change was linked to weight change.
Peptide
Exenatide (exendin-4)
Outcome
Not applicablePlaque volume association with body weight
Study
n: not reported in source
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · up to 18 monthsAs given in this study (human).
Measurements
Correlation r, plaque volume change vs body weight change
0.29 r
exenatide group
Source sentences
Summary
The change in plaque volume in the exenatide group was associated with changes in HbA_1c (r = 0.38, P = 0.0004), body weight, and overall plasma glucose (r = 0.29, P = 0.007 both).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54).
Report a problemFND-3349529406
13HumanObservational studyOther
In exenatide-treated patients, plaque volume change correlated with overall plasma glucose change.
In plain wordsIn patients taking exenatide, plaque volume change was linked to blood sugar change.
Peptide
Exenatide (exendin-4)
Outcome
Not applicablePlaque volume association with plasma glucose
Study
n: not reported in source
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · up to 18 monthsAs given in this study (human).
Measurements
Correlation r, plaque volume change vs overall plasma glucose change
0.29 r
exenatide group
Source sentences
Summary
The change in plaque volume in the exenatide group was associated with changes in HbA_1c (r = 0.38, P = 0.0004), body weight, and overall plasma glucose (r = 0.29, P = 0.007 both).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54).
Report a problemFND-3349529407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT02162550

Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

Phoenix VA Health Care Systemn = 148Jun 2014 to est. Sept 2019

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 14 Jun 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.